SOM Biotech Concludes 2020 with Advanced and Robust Pipeline
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
Programme SOM1311 for the Treatment of Phenylketonuria
SOM1311 is a small molecule pharmacological chaperone of Phenylalanine Hydroxylase for the treatment of Phenylketonuria.
Phenylketonuria (PKU) is characterised by an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated, PKU can lead to intellectual disability, seizures, behavioural problems and mental disorders.
More About This Company
Covid-19 Therapeutics
The current Covid-19 pandemic situation has shown that repurposing drugs can be crucial for delivering...
SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
SOM Biotech Announces in Vitro Confirmation of Drug Candidates for Covid-19 in Collaboration with Ewha Woman’s University
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of...